CONCORDBIO Concord Biotech Q2 FY25 results (Jul–Sep 2024) and concall
Concord Biotech delivered a robust Q2 FY25, characterized by strong top-line and bottom-line growth of 18%. The quarter was marked by a significant shift in revenue mix, with the formulation business scaling rapidly to 26% of sales. While this shift caused some gross margin compression due to the lower-margin nature of formulations compared to niche APIs, management remains confident in achieving double-digit API growth for the full year and sustaining its 25% long-term growth trajectory.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 310 |
| EBITDA | 137 |
| Net profit | 99 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
